190 related articles for article (PubMed ID: 26870138)
1. Thyroid Papillary Microcarcinoma: Etiology, Clinical Manifestations,Diagnosis, Follow-up, Histopathology and Prognosis.
Dideban S; Abdollahi A; Meysamie A; Sedghi S; Shahriari M
Iran J Pathol; 2016; 11(1):1-19. PubMed ID: 26870138
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of Etiology, Clinical Manifestations, Diagnosis, Follow-up, Histopathology and Prognosis Factors in Papillary Thyroid Microcarcinoma: A Systematic Review and Meta-analysis.
Didehban S; Abdollahi A; Meysamie A
Iran J Pathol; 2023; 18(4):380-391. PubMed ID: 38024552
[TBL] [Abstract][Full Text] [Related]
3. Incidental papillary microcarcinoma of the thyroid.
Ertorer ME; Tutuncu NB; Ozyilkan O
Asian Pac J Cancer Prev; 2007; 8(4):631-4. PubMed ID: 18260743
[TBL] [Abstract][Full Text] [Related]
4. Treatment for microcarcinoma of the thyroid--clinical experience.
Küçük NO; Tari P; Tokmak E; Aras G
Clin Nucl Med; 2007 Apr; 32(4):279-81. PubMed ID: 17413573
[TBL] [Abstract][Full Text] [Related]
5. Risk factors contributing to the difference in prognosis for papillary versus micropapillary thyroid carcinoma.
Karatzas T; Vasileiadis I; Kapetanakis S; Karakostas E; Chrousos G; Kouraklis G
Am J Surg; 2013 Oct; 206(4):586-93. PubMed ID: 23790258
[TBL] [Abstract][Full Text] [Related]
6. The BRAF(V600E) mutation in papillary thyroid microcarcinoma: does the mutation have an impact on clinical outcome?
Walczyk A; Kowalska A; Kowalik A; Sygut J; Wypiórkiewicz E; Chodurska R; Pięciak L; Góźdź S
Clin Endocrinol (Oxf); 2014 Jun; 80(6):899-904. PubMed ID: 24354346
[TBL] [Abstract][Full Text] [Related]
7. RET/PTC oncogene activation defines a subset of papillary thyroid carcinomas lacking evidence of progression to poorly differentiated or undifferentiated tumor phenotypes.
Tallini G; Santoro M; Helie M; Carlomagno F; Salvatore G; Chiappetta G; Carcangiu ML; Fusco A
Clin Cancer Res; 1998 Feb; 4(2):287-94. PubMed ID: 9516913
[TBL] [Abstract][Full Text] [Related]
8. [Clinical pathological characteristics of resectable papillary thyroid microcarcinoma].
Shi CL; Guo Y; Lyu YC; Nanding ZABYS; Gao WC; Shi TF; Qin HD; Liu SY
Zhonghua Zhong Liu Za Zhi; 2017 May; 39(5):361-366. PubMed ID: 28535653
[No Abstract] [Full Text] [Related]
9. The role of BRAF V600E mutation as a potential marker for prognostic stratification of papillary thyroid carcinoma: a long-term follow-up study.
Daliri M; Abbaszadegan MR; Bahar MM; Arabi A; Yadollahi M; Ghafari A; Taghehchian N; Zakavi SR
Endocr Res; 2014; 39(4):189-93. PubMed ID: 24679337
[TBL] [Abstract][Full Text] [Related]
10. Papillary thyroid microcarcinoma: how to diagnose and manage this epidemic?
Soares P; Celestino R; Gaspar da Rocha A; Sobrinho-Simões M
Int J Surg Pathol; 2014 Apr; 22(2):113-9. PubMed ID: 24401191
[TBL] [Abstract][Full Text] [Related]
11. [Thyroid microcarcinoma].
Lantsov DS
Arkh Patol; 2006; 68(4):54-7. PubMed ID: 16986502
[TBL] [Abstract][Full Text] [Related]
12. Papillary carcinoma thyroid with anastomosing channels: An unusual morphology.
Dalal V; Kaur M; Bansal A
J Lab Physicians; 2017; 9(2):140-142. PubMed ID: 28367032
[TBL] [Abstract][Full Text] [Related]
13. Expression of the membrane mucins MUC4 and MUC15, potential markers of malignancy and prognosis, in papillary thyroid carcinoma.
Nam KH; Noh TW; Chung SH; Lee SH; Lee MK; Hong SW; Chung WY; Lee EJ; Park CS
Thyroid; 2011 Jul; 21(7):745-50. PubMed ID: 21615302
[TBL] [Abstract][Full Text] [Related]
14. High recurrent rate of multicentric papillary thyroid carcinoma.
Lin JD; Chao TC; Hsueh C; Kuo SF
Ann Surg Oncol; 2009 Sep; 16(9):2609-16. PubMed ID: 19533244
[TBL] [Abstract][Full Text] [Related]
15. Is papillary thyroid microcarcinoma a biologically different disease? A propensity score-matched analysis.
Hsu YC; Lee JJ; Chien MN; Chen MJ; Leung CH; Cheng SP
J Surg Oncol; 2019 Nov; 120(6):1023-1030. PubMed ID: 31407354
[TBL] [Abstract][Full Text] [Related]
16. Clinicopathological Features and Prognosis of Papillary Thyroid Microcarcinoma for Surgery and Relationships with the BRAFV600E Mutational Status and Expression of Angiogenic Factors.
Shi C; Guo Y; Lv Y; Nanding A; Shi T; Qin H; He J
PLoS One; 2016; 11(12):e0167414. PubMed ID: 27936049
[TBL] [Abstract][Full Text] [Related]
17. [Our experience on surgical treatment of papillary thyroid microcarcinoma].
Ciuffreda L; De Martino D; Bonfitto N; Scaramuzzi R
G Chir; 2011; 32(1-2):41-4. PubMed ID: 21352707
[TBL] [Abstract][Full Text] [Related]
18. Deciphering novel biomarkers of lymph node metastasis of thyroid papillary microcarcinoma using proteomic analysis of ultrasound-guided fine-needle aspiration biopsy samples.
Lin P; Yao Z; Sun Y; Li W; Liu Y; Liang K; Liu Y; Qin J; Hou X; Chen L
J Proteomics; 2019 Jul; 204():103414. PubMed ID: 31195151
[TBL] [Abstract][Full Text] [Related]
19. Skeletal Muscle Metastasis in Papillary Thyroid Microcarcinoma Evaluated by F18-FDG PET/CT.
Hitu L; Cainap C; Apostu D; Gabora K; Bonci EA; Badan M; Mester A; Piciu A
Diagnostics (Basel); 2020 Feb; 10(2):. PubMed ID: 32059570
[TBL] [Abstract][Full Text] [Related]
20. Clinicopathological features of papillary thyroid microcarcinoma with a diameter less than or equal to 5 mm.
Yan L; Blanco J; Reddy V; Al-Khudari S; Tajudeen B; Gattuso P
Am J Otolaryngol; 2019; 40(4):560-563. PubMed ID: 31103218
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
